Compare NAVI & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAVI | ANNX |
|---|---|---|
| Founded | 1973 | 2011 |
| Country | United States | United States |
| Employees | 670 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 771.2M | 730.4M |
| IPO Year | N/A | 2020 |
| Metric | NAVI | ANNX |
|---|---|---|
| Price | $8.05 | $5.01 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $12.14 | ★ $16.50 |
| AVG Volume (30 Days) | 844.6K | ★ 2.4M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 7.78% | N/A |
| EPS Growth | N/A | ★ 42.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $74.32 | N/A |
| Revenue Next Year | $15.75 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.86 | $1.29 |
| 52 Week High | $16.07 | $7.18 |
| Indicator | NAVI | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 30.14 | 43.70 |
| Support Level | $7.86 | $4.77 |
| Resistance Level | $8.40 | $5.28 |
| Average True Range (ATR) | 0.24 | 0.37 |
| MACD | 0.09 | -0.05 |
| Stochastic Oscillator | 33.33 | 5.48 |
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in two segments: Federal Education Loans, and Consumer Lending. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.